Skip to main content
Premium Trial:

Request an Annual Quote

Court Bars Abbott From Selling HCV Genotyping Products That Infringe Innogenetics IP

NEW YORK (GenomeWeb News) — Innogenetics today said that a US District Court in Wisconsin has barred Abbott Laboratories from using or selling its hepatitis C genotyping technology anywhere in the world after an earlier verdict found Abbott to infringe a US patent held by Innogenetics.
Innogenetics sued Abbott Laboratories in 2005 for infringing US Patent No. 5,846,704. In September 2006 a jury awarded Innogenetics $7 million, and last week the judge in the case upheld that award, denied Abbott a new trial on “infringement and validity,” and set the date to consider barring Abbott permanently from selling the infringing products.  
Innogenetics also sued Third Wave Technologies for allegedly infringing the same IP, but Third Wave settled the case under a non-exclusive licensing agreement and optional extension with Innogenetics.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.